Sarclisa (isatuximab) has been approved in China for use in combination with the VRd regimen to treat newly diagnosed multiple myeloma patients w ...

The committee reviewed data showing a 94 percent complete response rate as a third- or later-line treatment for refractory follicular lymphoma.

Drawing on 35 years of experience in the development and production of high-temperature ceramic fibre, RATH is always looking ...

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma ...

In a report released yesterday, Carlos De Alba from Morgan Stanley maintained a Buy rating on United States Steel (X – Research Report), with a ...

Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma: Houston Thursday, January 30, 2025, 17:00 Hrs [IST] ...

The global extrusion equipment market is set to witness a substantial compound annual growth rate (CAGR) of 5.3% throughout ...

RHI Magnesita, the leading global supplier of high-grade refractory products, systems and solutions, is pleased to announce the completion of the acquisition of the US-based Resco Group, from an ...

Balmoral Funds has sold Resco Group, a Pittsburgh-based producer of shaped and unshaped refractories, to RHI Magnesita, a supplier of refractory products, systems and solutions, for $410 million. This ...

Minerals Technologies (MTX – Research Report) received a Buy rating and a $103.00 price target from Truist Financial analyst Pete Osterland ...